Stock analysis, trade plans, and proprietary indicators by Trend Edge.
Trend Edge rates RNAZ Bearish with a Setup Score of 56, net conviction 51, actionability 62. How the Setup Score works →
| Total Setup Score | 56 |
|---|---|
| Directional Bias | Bearish |
| Net Conviction | 51 |
| Actionability | 62 (in range) |
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising brea… Read full Trend Edge analysis →
| Current Price | $1.73 |
|---|---|
| Market Cap | $29.0M |
| Float | 2.2M |
| Shares Outstanding | 16.9M |
| vs. Analyst Target | +478.0% to analyst PT |
| Dividend Rate | None |
| Analyst Target Price | $10.00 |
| Year | Revenue | Net Income | Gross Profit | EBITDA |
|---|---|---|---|---|
| 2020 | N/A | -$2.3M | N/A | -$1.9M |
| 2021 | N/A | -$6.8M | -$42,470 | -$6.7M |
| 2022 | N/A | -$17.6M | -$98,606 | -$17.5M |
| 2023 | N/A | -$18.5M | -$516,746 | -$18.0M |
| 2024 | N/A | -$16.8M | -$534,857 | -$16.2M |
| 2025 | N/A | -$34.7M | -$114,177 | -$34.3M |
| Quarter | Revenue | Net Income |
|---|---|---|
| Sep 2025 | N/A | -$4.9M |
| Dec 2025 | N/A | -$13.4M |
| Mar 2026 | N/A | -$17.8M |
| Jun 2026 | N/A | -$6.7M |
| Insider Ownership | 1.8% |
|---|---|
| Institutional Ownership | 0.4% |
| Short Float | 2.4% |
| % of All Funds Holding | 0.10% |
| Number of Funds Holding | 9 |
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
| Timeframe | SMA | Value | Trend Context |
|---|---|---|---|
| Weekly | 10-Week SMA | $1.79 | Near-term / short-term trend |
| Weekly | 40-Week SMA | $5.90 | Medium-term trend |
| Weekly | 80-Week SMA | $7.82 | Cyclical trend (business cycle) |
| Weekly | 200-Week SMA | $41300.98 | Secular trend (multi-year) |
| Monthly | 10-Month SMA | $5.71 | Near-term monthly trend |
| Monthly | 20-Month SMA | $7.79 | Medium-term monthly trend |
| Monthly | 40-Month SMA | $4742.73 | Secular monthly trend |
Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
| Price Level | Type | Volume Ratio | Age |
|---|---|---|---|
| $13.30 | resistance | 2.70x | 17 months ago |
| $56.00 | resistance | 7.48x | 18 months ago |
| $194.00 | resistance | 3.27x | 20 months ago |
| $304.00 | resistance | 2.20x | 21 months ago |
| Timeframe | Avg Return | Median | Win Rate | Best | Worst |
|---|---|---|---|---|---|
| Gap | -1.48% | -0.62% | 38.10% | 9.34% | -24.23% |
| 1 Day | -2.52% | 1.84% | 57.14% | 9.65% | -43.31% |
| 1 Week | -8.47% | -5.64% | 33.33% | 21.93% | -80.31% |
| 2 Weeks | -10.28% | -9.40% | 28.57% | 41.71% | -81.86% |
| 1 Month | -13.26% | -13.99% | 35.00% | 67.51% | -82.18% |
Next earnings: November 13, 2026 (14 days away)
Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).
| Day | Avg Return | Win Rate | Samples |
|---|---|---|---|
| Monday | -0.08% | 40.6% | 249 |
| Tuesday | -0.89% | 44.7% | 275 |
| Wednesday | 0.30% | 42.5% | 273 |
| Thursday | -0.36% | 39.8% | 266 |
| Friday | -1.18% | 37.7% | 268 |
Institutional holder breakdown coming soon.
Total institutional ownership: 0.4%
Total insider ownership: 1.8%
Founder-led management: Zdravka Medarova (Scientific Co-Founder and Chief Scientific Officer), Anna Moore (Scientific Co-Founder, Scientific Advisor and Chair of Scientific Advisory Board)
Full insider transaction history and smart buy/sell sentiment summary available on Trend Edge.
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Transcode Therapeutics Inc (RNAZ) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.
Get the full AI Consult analysis for RNAZ on Trend Edge →